DUSA Pharmaceuticals News

WILMINGTON, Mass., May 1, 2012 -- DUSA Pharmaceuticals, Inc. announces that its first quarter 2012 corporate highlights and financial results press release will be issued on Tuesday, May 8th at 6:30 a.m. to be followed by a conference call and audio webcast at 8:30 a.m. Conference call dial in and webcast log in details are as follows: A telephone ... (more)

DUSA Pharmaceuticals, Inc. , a dermatology company that is developing and marketing its Levulan Photodynamic Therapy platform, announced today that patient enrollment is complete in its Phase 2 clinical trial studying the broad area application with 1, 2 and 3-hour drug incubation for the treatment of actinic keratoses of the face or scalp.

There are certain dusty corners of biopharma where most investors just don't look all that often, and eye care and skin care are high on the list.

DUSA Pharmaceuticals, Inc. , a dermatology company that is developing and marketing Levulan Photodynamic Therapy , previously announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 2012 Maxim Group Growth Conference on Monday, March 26, 2012 at the Grand Hyatt Hotel in New York City.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia WILMINGTON, Mass., March 19, 2012 -- DUSA Pharmaceuticals, Inc.A , a dermatology company that is developing and marketing LevulanA Photodynamic Therapy , announced that Bob ... (more)